Intravenous colistin (polymyxin E) has renewed interest as a last-line treatment against antimicrobial-resistant Gram-negative bacterial infections, despite limited literature on pediatric prescribing practices. Point-prevalence surveys were used to obtain intravenous colistin prescribing data from 78 children and neonates, showing high variability, and 60.3% received doses below the Food and Drug Administration and the European Medicines Agency recommendations.
Evidence of dose variability and dosing below the FDA and EMA recommendations for intravenous colistin (Polymyxin E) use in children and neonates
Dona' D.
2020
Abstract
Intravenous colistin (polymyxin E) has renewed interest as a last-line treatment against antimicrobial-resistant Gram-negative bacterial infections, despite limited literature on pediatric prescribing practices. Point-prevalence surveys were used to obtain intravenous colistin prescribing data from 78 children and neonates, showing high variability, and 60.3% received doses below the Food and Drug Administration and the European Medicines Agency recommendations.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
